US 12,253,528 B2
Methods and compositions for treating asthma and allergic diseases
Bertrand Cariou, Nantes (FR); Antoine Magnan, Nantes (FR); Grégory Bouchaud, Nantes (FR); and Cédric Le May, Nantes (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris (FR); UNIVERSITE DE NANTES, Nantes (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE L'ALIMENTATION ET L'ENVRIONMENT, Paris (FR); and CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, Nantes (FR)
Appl. No. 17/273,082
Filed by INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); NANTES UNIVERSITE, Nantes (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, Paris (FR); and CHU NANTES, Nantes (FR)
PCT Filed Sep. 4, 2019, PCT No. PCT/EP2019/073546
§ 371(c)(1), (2) Date Mar. 3, 2021,
PCT Pub. No. WO2020/049026, PCT Pub. Date Mar. 12, 2020.
Claims priority of application No. 18306169 (EP), filed on Sep. 5, 2018.
Prior Publication US 2021/0278420 A1, Sep. 9, 2021
Int. Cl. G01N 33/68 (2006.01); A61P 37/08 (2006.01); C07K 16/40 (2006.01); C12N 15/113 (2010.01)
CPC G01N 33/6893 (2013.01) [A61P 37/08 (2018.01); C07K 16/40 (2013.01); C12N 15/1137 (2013.01); C07K 2317/76 (2013.01); C12N 2310/14 (2013.01); G01N 2333/96433 (2013.01); G01N 2800/122 (2013.01); G01N 2800/24 (2013.01); G01N 2800/56 (2013.01)] 11 Claims
 
1. A method for assessing or predicting severity of an allergic disease in a subject, comprising
i) determining a PCSK9 level in a biological sample obtained from the subject,
ii) comparing the level determined at step i) with a predetermined reference value,
iii) concluding that the subject has or is susceptible to have a severe allergic disease when the level of PCSK9 is higher than the predetermined reference value, wherein the allergic disease is selected from the group consisting of a food allergy, allergic rhinitis and asthma, and
iv) administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a PCSK9 inhibitor.